These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18288079)

  • 1. Early access to new medicines.
    Breckenridge A; Walley T
    Clin Pharmacol Ther; 2008 Jul; 84(1):23-5. PubMed ID: 18288079
    [No Abstract]   [Full Text] [Related]  

  • 2. Access to essential medicines for children: the world health organization's global response.
    Zucker H; Rägo L
    Clin Pharmacol Ther; 2007 Nov; 82(5):503-5. PubMed ID: 17952106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could the WHO model list of essential medicines do more for the safe and appropriate use of injections?
    Logez SM; Hutin YJ; Holloway K; Gray R; Hogerzeil HV
    J Clin Pharmacol; 2004 Oct; 44(10):1106-13. PubMed ID: 15342611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US proposal to expand access to untested drugs draws fire.
    Waltz E
    Nat Med; 2007 Feb; 13(2):111. PubMed ID: 17290254
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug treatment of newborn infants--a chance taking?].
    Kalikstad B; Hansen TW
    Tidsskr Nor Laegeforen; 2003 Oct; 123(19):2738-40. PubMed ID: 14600750
    [No Abstract]   [Full Text] [Related]  

  • 6. Availability of essential medicines in Ethiopia: an efficiency-equity trade-off?
    Carasso BS; Lagarde M; Tesfaye A; Palmer N
    Trop Med Int Health; 2009 Nov; 14(11):1394-400. PubMed ID: 19754520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removing barriers? An overview of the Canadian Access to Medicines Regime.
    Penner MD; Armstrong PG
    Health Law Can; 2008 Jun; 28(3-4):112-22. PubMed ID: 19051971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug access in poor countries].
    Sebbag R
    Bull Acad Natl Med; 2007 Nov; 191(8):1601-2. PubMed ID: 18666459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 11. [Access to medicines in France].
    Bouvenot G; Bouvenot J
    Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charging for investigational drugs under an investigational new drug application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relatively good safety in Swedish phase I trials. A survey of studies reported to the Medical Products Agency during 3 years].
    Glazer A; Hedenmalm K
    Lakartidningen; 2008 Sep 10-16; 105(37):2482-4. PubMed ID: 19006863
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanding access to investigational drugs for treatment use: a policy analysis and legislative proposal.
    Winniford A
    Health Matrix Clevel; 2009; 19(1):205-46. PubMed ID: 19459546
    [No Abstract]   [Full Text] [Related]  

  • 15. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
    Tetteh E
    Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
    [No Abstract]   [Full Text] [Related]  

  • 16. The influence of health insurance towards accessing essential medicines: the experience from Shenzhen labor health insurance.
    Zhu M; Dib HH; Zhang X; Tang S; Liu L
    Health Policy; 2008 Dec; 88(2-3):371-80. PubMed ID: 18514354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Near-thorough QT study as part of a first-in-man study.
    Malik M; Hnatkova K; Ford J; Madge D
    J Clin Pharmacol; 2008 Oct; 48(10):1146-57. PubMed ID: 18757785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding flaws: the limitations of compulsory licensing for improving access to medicines--an international comparison.
    Ng E; Kohler JC
    Health Law J; 2008; 16():143-72. PubMed ID: 19536980
    [No Abstract]   [Full Text] [Related]  

  • 19. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicine access and utilization in a population covered by primary health care in Brazil.
    Bertoldi AD; de Barros AJ; Wagner A; Ross-Degnan D; Hallal PC
    Health Policy; 2009 Mar; 89(3):295-302. PubMed ID: 18722031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.